Document Detail

The utility of sulfonate salts in drug development.
MedLine Citation:
PMID:  20112423     Owner:  NLM     Status:  MEDLINE    
The issue of controlling genotoxic impurities in novel active pharmaceutical ingredients (APIs) is a significant challenge. Much of the current regulatory concern, has been focused on the formation and control of genotoxic sulfonate esters. This is linked with the withdrawal of Viracept (Nefinavir mesilate) from European markets in mid-2007, over concerns about elevated levels of ethyl methanesulfonate (EMS). This issue has resulted in calls from European regulators to assess risk mitigation strategies for all marketed products employing a sulfonic acid counter-ion to ensure that the sulfonate esters that could be potentially formed are controlled to threshold of toxicological concern (TTC)-based limits. This has even led to calls to avoid sulfonic acids as salt counter-ions. However, sulfonic acid salts possess a range of properties that are useful to both synthetic and formulation chemists. Whilst sulfonate salts are not a universal panacea to some of the problems of salt formation they do offer significant advantages as alternatives to other salt forming moieties under certain circumstances. This review thus sets out to define some of the advantages provided through utilization of sulfonic acids, explaining the importance of their retention as part of a thorough salt selection process.
David P Elder; Ed Delaney; Andrew Teasdale; Steve Eyley; Van D Reif; Karine Jacq; Kevin L Facchine; Rolf Schulte Oestrich; Patrick Sandra; Frank David
Related Documents :
18047093 - Preparation of liposomes containing oleanolic acid via micelle-to-vesicle transition.
12687073 - Influence of amine salt of 2,4-dichlorphenoxyacetic acid on functional activity of peri...
15621743 - Long term changes in the distribution and delta(15)n values of individual soil amino ac...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of pharmaceutical sciences     Volume:  99     ISSN:  1520-6017     ISO Abbreviation:  J Pharm Sci     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-04-30     Completed Date:  2010-08-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985195R     Medline TA:  J Pharm Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2948-61     Citation Subset:  IM    
Copyright Information:
(c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association
GlaxoSmithKline Research and Development, Park Road, Ware, Hertfordshire SG12 0DP, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Discovery*
Salts / chemistry*,  pharmacology
Sulfonic Acids / chemistry*,  pharmacology
Reg. No./Substance:
0/Salts; 0/Sulfonic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dimerization of protein G B1 domain at low pH: A conformational switch caused by loss of a single hy...
Next Document:  5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepat...